EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Anlotinib Inhibits Cisplatin Resistance in Non-Small-Cell Lung Cancer Cells by Inhibiting MCL-1 Expression via MET/STAT3/Akt Pathway

Lile Wang iD, Lu Xu iD, Shuhua Han iD, Xiaoli Zhu iD

Canadian Respiratory Journal · 2024

DOI: 10.1155/2024/2632014 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Canadian Respiratory Journal, 2024. Verfasst von Lile Wang und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory Medicine, Zhongda Hospital, School of Medicine, Southeast University, Nanjing 210009, China. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Indoles, Quinolines. Die Arbeit nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Anlotinib is an effective targeted therapy for advanced non-small-cell lung cancer (NSCLC) and has been found to mediate chemoresistance in many cancers. However, the underlying molecular mechanism of anlotinib mediates cisplatin (DDP) resistance in NSCLC remains unclear.

Methods

Cell viability was assessed by the cell counting kit 8 assay. Cell proliferation, migration, and invasion were determined using the colony formation assay and transwell assay. The mRNA expression levels of mesenchymal-epithelial transition factor (MET) and myeloid cell leukemia-1 (MCL-1) were measured by quantitative real-time PCR. Protein expression levels of MET, MCL-1, and STAT3/Akt pathway-related markers were examined using western blot analysis.

Results

Our data showed that anlotinib inhibited the DDP resistance of NSCLC cells by regulating cell proliferation and metastasis. Moreover, MET and MCL-1 expression could be decreased by anlotinib treatment. Silencing of MET suppressed the activity of the STAT3/Akt pathway and MCL-1 expression. Furthermore, MET overexpression reversed the inhibitory effect of anlotinib on the DDP resistance of NSCLC cells, and this effect could be eliminated by MCL-1 knockdown or ACT001 (an inhibitor for STAT3/Akt pathway).

Conclusion

Our results confirmed that anlotinib inhibited DDP resistance in NSCLC cells, which might decrease MCL-1 expression via mediating the MET/STAT3/Akt pathway.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsIndolesQuinolinesHumansCisplatinProto-Oncogene Proteins c-aktMyeloid Cell Leukemia Sequence 1 ProteinDrug Resistance, NeoplasmCell ProliferationSTAT3 Transcription Factor

Substanzen

CisplatinProto-Oncogene Proteins c-aktanlotinibMyeloid Cell Leukemia Sequence 1 ProteinSTAT3 protein, humanSTAT3 Transcription FactorIndolesQuinolines

Autor:innen und Institutionen

  • Department of Respiratory Medicine, Zhongda Hospital, School of Medicine, Southeast University, Nanjing 210009, China.
  • School of Medicine, Southeast University, Nanjing 210009, China.

ORCID-Profile: Lile Wang, Lu Xu, Shuhua Han, Xiaoli Zhu

Zitieren

APA

Wang, L., Xu, L., Han, S., & Zhu, X. (2024). Anlotinib Inhibits Cisplatin Resistance in Non-Small-Cell Lung Cancer Cells by Inhibiting MCL-1 Expression via MET/STAT3/Akt Pathway. Canadian Respiratory Journal. https://doi.org/10.1155/2024/2632014

Vancouver

Wang L, Xu L, Han S, Zhu X. Anlotinib Inhibits Cisplatin Resistance in Non-Small-Cell Lung Cancer Cells by Inhibiting MCL-1 Expression via MET/STAT3/Akt Pathway. Canadian Respiratory Journal. 2024. doi:10.1155/2024/2632014

BibTeX
@article{Wang2024,
  author = {Wang, Lile and Xu, Lu and Han, Shuhua and Zhu, Xiaoli},
  title = {Anlotinib Inhibits Cisplatin Resistance in Non-Small-Cell Lung Cancer Cells by Inhibiting MCL-1 Expression via MET/STAT3/Akt Pathway},
  journal = {Canadian Respiratory Journal},
  year = {2024},
  doi = {10.1155/2024/2632014}
}
Kostenlos starten →